Innovent’s IL-23 Drug Picankibart Shows Promising Results in Phase 3 Trial for Moderate to Severe Plaque Psoriasis

Clinical Trial Success:
Innovent's picankibart, an anti-IL-23p19 monoclonal antibody, has successfully met all primary and key secondary endpoints in the Phase 3 CLEAR-1 trial for moderate to severe plaque psoriasis.

Efficacy:
80.3% of patients who received picankibart achieved a 90% or greater improvement in their Psoriasis Area and Severity Index (PASI) score at 16 weeks, compared to 2% of participants who received placebo.

Long-term Efficacy:
The strong efficacy was maintained through Week 52, with 84.9% of patients in the 200-mg group still having a PASI score of 90% or above.

NDA Acceptance:
The New Drug Application (NDA) for picankibart has been accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).

Dosing Interval:
Picankibart offers the longest maintenance dosing interval (once every 12 weeks) among the same class of biologics, providing enhanced convenience and quality of life for patients.

Regulatory Progress:
Innovent is preparing for regulatory approval in China, aiming to provide a safe and effective treatment option for Chinese patients with moderate to severe plaque psoriasis.